Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine Plus Mosunetuzumab in R/R DLBCL
NCT05672251Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2024
- Primary completion
- Aug 2029
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine and mosunetuzumab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by City of Hope. Primary endpoints: Unacceptable toxicity and Overall response rate. Started Jan 2024; status: recruiting.
02
Drugs
loncastuximab tesirinemosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05672251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672251.